Virtual Library
Start Your Search
M.D. Ter-Ovanesov
Author of
-
+
P3.15 - SCLC/Neuroendocrine Tumors (ID 731)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: SCLC/Neuroendocrine Tumors
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.15-016 - The Role of Surgery in Combination Treatment of Patients with Small Cell Lung Cancer (ID 8341)
09:30 - 09:30 | Author(s): M.D. Ter-Ovanesov
- Abstract
Background:
Small cell lung cancer (SCLC) as the most aggressive tumor deserves a special attention. The aim of this research was to define the place of surgery of patients with SCLC in order to improve the results of treatment.
Method:
Clinical material for research consists of 49 patients in stage IA-IIIA with SCLC, which were radically operated in Ugra (region Russia) between 1999 and 2015. Among patients predominate males 41 (83,7%), versus females – eight (16,3%).
Result:
All patients underwent radical operations R0. All resection types were included (pneumonectomy, bilobectomy, and lobectomy). By 37 patients (75,5%) systematic nodal dissection (SND) was carried out, by 5 (10,2%) - mediastinal lymph node sampling (MLS) and by 7 patients mediastinal node dissection was not carried out. By SCLC combination treatment was used more often – 35 (71,4%). By that only in 11 cases additional adjuvant of thoracic radiotherapy was used. In 14 cases only surgical resection was used (28,6%). 5-year and 10-year overall survival (OS) rate was 47,6% and 37,2%. Median survival rate was 49 months. Five and ten-year OS rate by surgery combined with adjuvant chemotherapy was 53,8% and 39,5%, as compared to only surgical treatment – 35,6%. Median survival rate was 67 and 25 months, respectively. At I stage satisfactory results were achieved: 5-year and 10-year OS rate was 68,8% and 62,5% (р<0,05), – that corresponds with results of treatment of patients with non-small cell lung cancer with similar stage of process. Median survival rate was not achieved. At II stage 5-year and 10-year OS rate was 41,7 and 41,7%. Median survival rate was 36 months. At III stage unsatisfactory results were obtained. 5-year OS rate was 25,1%. Median survival rate was only 13 months.
Conclusion:
SCLC at I and II stages is the indication to radical treatment, mandatory including surgical resection with SND and adjuvant chemotherapy. The main method of treatment at III stage is chemotherapy or chemoradiotherapy.
